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Prolyl hydroxylation is a critical posttransla-
tional modification that affects structure, func-
tion, and turnover of target proteins. Prolyl
3-hydroxylation occurs at only one position in
the triple-helical domain of fibrillar collagen
chains, and its biological significance is un-
known. CRTAP shares homology with a family
of putative prolyl 3-hydroxylases (P3Hs), but it
does not contain their common dioxygenase
domain. Loss of Crtap in mice causes an osteo-
chondrodysplasia characterized by severe os-
teoporosis and decreased osteoid production.
CRTAP can form a complex with P3H1 and cy-
clophilin B (CYPB), and Crtap/ bone and
cartilage collagens show decreased prolyl
3-hydroxylation. Moreover, mutant collagen
shows evidence of overmodification, and colla-
gen fibrils in mutant skin have increased diam-
eter consistent with altered fibrillogenesis. In
humans, CRTAP mutations are associated
with the clinical spectrum of recessive os-
teogenesis imperfecta, including the type II
and VII forms. Hence, dysregulation of prolyl
3-hydroxylation is a mechanism for connective
tissue disease.INTRODUCTION
Collagens and proteins with collagenous domains consti-
tute a large superfamily characterized by the unique repeat-
ing Gly-X-Y motif that is required for the formation of a
triple-helical tertiary structure and in which Y is often 4-
hydroxyproline (Eyre, 2004; Myllyharju and Kivirikko, 2004).
The fibril-forming collagens (types I, II, III, V, and XI) are an
important group characterized by a continuous triple helical
domain that extends for more than 1000 amino acids.
Mutations in the fibrillar collagen genes were among the
first identified to cause osteodysplasias, i.e., osteogenesis
imperfecta (OI), due to COL1A1 and COL1A2 mutations
(Pihlajaniemi et al., 1984), and chondrodysplasias, i.e., the
spondyloepiphyseal dysplasia spectrum, due to COL2A1
mutations (Dreyer et al., 1998; Lee et al., 1989). Mutations
in these genes result either in quantitative deficiencies or
sequence alterations leading to structural defects of the
triple helix, altered secretion, and abnormal fibril formation
and/or assembly (Byers and Cole, 2002). More recently,
defects in the posttranslational modification machinery of
collagens have been associated with other disorders,
e.g., Ehlers Danlos syndrome type VI (Hyland et al., 1992).
Nascent procollagen a chains undergo extensive post-
translational modification on entry into the rough endo-
plasmic reticulum (rER) (Lamande and Bateman, 1999;
Myllyharju and Kivirikko, 2004). Enzymatic modifications
include prolyl 4-hydroxylation, prolyl 3-hydroxylation,
lysyl hydroxylation, and glycosylation by collagenCell 127, 291–304, October 20, 2006 ª2006 Elsevier Inc. 291
glucosyl/galactosyl-transferase. The hydroxylating reac-
tions are mediated by enzymes containing the catalytic
2-oxoglutarate and Fe(II)-dependent dioxygenase domain.
These enzymes require Fe(II), 2-oxoglutarate, molecular
oxygen (O2), and ascorbate to oxidatively decarboxylate
2-oxoglutarate to form succinate (Aravind and Koonin,
2001). One atom of oxygen from molecular O2 is then trans-
ferred to succinate, while the other is used to hydroxylate
the protein substrate. Hydroxylation reactions affect not
only the thermal and structural stability of extracellular col-
lagens but also, for instance, the turnover of proteins such
as the hypoxia inducible factor (HIF) (Semenza, 2001). Col-
lagen prolyl 4-hydroxylation occurs in the endoplasmic re-
ticulum and is mediated by a tetrameric prolyl 4-hydroxy-
lase (P4H) complex (Myllyharju, 2003). Almost complete
4-hydroxylation of all prolines in the Y position is necessary
for fibrillar collagen stability at 37C (Berg and Prockop,
1973a; Berg and Prockop, 1973b). Moreover, this modifi-
cation is found in over 30 additional proteins with collagen
domains.
The functional consequences of prolyl 3-hydroxylation
of collagens are less understood. 3-Hyp occurs at the X
position in Gly-X-Y triplets and is most abundant in type
IV collagen where there are 10–15 residues per 1000
amino acids of the triple-helical domain (Kefalides, 1973;
Kresina and Miller, 1979). In contrast, the fibrillar types I
and II collagens have only one 3-Hyp residue per a1 chain
(Kefalides, 1973). This raises the possibility that 3-Hyp
may serve divergent functions in fibrillar versus network
collagens. Biophysical studies of synthetic Gly-3-Hyp-
Pro polypeptides suggest that 3-Hyp can destabilize the
triple helix in contrast to the stabilizing effect of 4-Hyp
(Jenkins et al., 2003; Mizuno et al., 2004).
A family of genes that encode for proteins with collagen
prolyl 3-hydroxylase (P3H) activity, including P3H1 (Lepre-
can), has been recently reported (Vranka et al., 2004).
Leprecan was originally described as a putative base-
ment membrane-associated proteoglycan (Wassenhove-
McCarthy and McCarthy, 1999), and subsequently, as
a potential growth suppressor gene on chromosome 1,
GROS1 (Kaul et al., 2000). It shares the catalytic dioxy-
genase domain found in collagen prolyl 4-hydroxylases
and lysyl hydroxylases.
In a differential expression screen of hypertrophic versus
proliferating chick embryo chondrocytes, we isolated
a cDNA coding for cartilage associated protein (CASP or
CRTAP) (Castagnola et al., 1997; Morello et al., 1999; To-
nachini et al., 1999). This protein is characterized by a sig-
nal peptide and a tetratricopeptide-like helical domain
(Andrade et al., 2001), which share high similarity with the
amino-terminal half of Leprecan. CRTAP copurifies with
protein fractions containing P3H activity but does not
share the enzymatically active domain (Vranka et al., 2004).
Osteogenesis imperfecta is a major cause of brittle
bone disease. The clinical spectrum of severe to mild OI
is described by clinical types II, III, IV, and I. Until now,
OI has been shown to be caused only by mutations in
the type I collagen genes, COL1A1 and COL1A2 (Byers292 Cell 127, 291–304, October 20, 2006 ª2006 Elsevier Inc.and Cole, 2002). However, newly defined types of OI,
including types V, VI, and VII, have suggested increasing
genetic heterogeneity, but candidate genes have not yet
been identified (Glorieux et al., 2000; Glorieux et al.,
2002; Ward et al., 2002).
In this study, we show that Crtap null mice have chon-
dro-osseous dysplasia with rhizomelia, kyphosis, and se-
vere osteopenia. At a biochemical level, they lack fibrillar
collagen prolyl 3-hydroxylation, suggesting an essential
role in the hydroxylation of specific prolyl residues and
an interaction between CRTAP and P3H1. We further
show that in humans, CRTAP mutations cause recessive
OI, ranging from neonatal lethal cases (OI type II) to
a milder phenotype (OI type VII) depending upon the
nature of mutation.
RESULTS
Crtap Is Expressed in the Skeleton, and Loss of Its
Function Causes an Osteochondrodysplasia with
Severe Osteopenia
On Northern analysis, Crtap is expressed in most tissues
to varying degrees (Morello et al., 1999). By mRNA in
situ hybridization (ISH), it is highly expressed in growth-
plate proliferating chondrocytes and in cells at the chon-
dro-osseous junction (Figures 1A and 1B). At E15.5, it is
expressed strongly in the presumptive bone collar of the
diaphyses, where vascular and osteoblast invasion is initi-
ated (Figure 1A, arrow). Its expression is low in hypertro-
phic chondrocytes (Figures 1A and 1C, arrowhead), and
RT-PCR analysis confirmed expression in both osteo-
blasts and osteoclasts (Figure 1H). Immunohistochemical
analyses using two different anti-CRTAP rabbit antisera
displayed identical staining patterns and confirmed the
distribution seen by ISH. Most of the CRTAP protein is lo-
cated within the cells, although some signal is detected in
the extracellular matrix (Figure 1C).
To determine the in vivo function ofCrtap, we generated
Crtap mutant mice by homologous recombination (Fig-
ures 1D–1F). Northern analysis of whole embryo RNA as
well as RT-PCR of mutant osteoblast RNA confirmed ab-
sence of Crtap mRNA in mutant mice (Figure 1G). Crtap
null mice are born at the expected Mendelian ratios, and
they develop progressive and severe kyphoscoliosis
over the first 6 months of age (Figures 2A and 2B). More-
over, they exhibit prenatal and postnatal growth delay that
is characterized by shortening of long bone segments,
affecting in particular the proximal segment of the limb.
The ratio between femoral versus tibial lengths in mutant
versus wild-type (WT) mice is consistent with rhizomelia
(WT = 0.82 ± 0.014; mutant = 0.77 ± 0.018; N = 6
each group; p < 0.01; Figures 2C and 2D). The growth plate
shows slightly disorganized growth columns of proliferat-
ing chondrocytes with areas of focal cell drop out, while
the zone of hypertrophy remains fairly intact (Figure 2F).
Skeletal radiographs and Von Kossa-stained calcified
bone sections showed striking evidence of osteoporosis
(Figures 2D and 2E). Mutant mice have decreased bone
Figure 1. Crtap Expression during Skeletal Development and Generation of Crtap/ Mice
(A and B) Serial mouse-limb sections at different stages of development stained with H&E (upper panels) or hybridized to Crtap (lower panels). Crtap
mRNA (red), localizes to areas of chondrogenesis and to sites of vascular invasion where bone collar has formed (arrow) at E15.5. Note low expression
of Crtap in hypertrophic chondrocytes (arrowheads). At P1, Crtap also strongly localizes to primary and secondary spongiosa where active bone
formation takes place.
(C) P1 mouse-femur sections stained with a CRTAP polyclonal antibody (lower panel) or preimmune serum (upper panel). CRTAP was localized to
proliferating chondrocytes (P) and bone (B and inset) but not hypertrophic chondrocytes (H).
(D) Schematic diagram of the construct used to generate Crtap knockout mice.
(E) Southern blot of targeted ES cell clone (lane 2) versus WT clones (lanes 1 and 3) digested with the listed enzyme and hybridized with the 30 or
50-flanking probe, respectively.
(F) Southern-blot genotyping of pups generated by intercross of Crtap+/ mice.
(G) Northern blot showing decreased and absence ofCrtapmRNA in heterozygous and null mice total embryo RNA, respectively.Gapdh hybridization
is the control for loading.
(H) RT-PCR showing Crtap expression in WT osteoblasts (OB) and osteoclasts (OC) but absence in Crtap/ OB.volume/tissue volume (BV/TV), trabecular thickness
(Tb.Th), and trabecular number (Tb.N), and increased tra-
becular separation (Tb.sp) (Figure 3A). Kinetic indices of
bone formation revealed a reduced bone formation rate
(BFR) due to a reduction in the mineral apposition rate
(MAR). Crtap mutant mice have normal mineralizing sur-
faces (MS/BS) consistent with the normal osteoblast
numbers that were observed along trabeculae (Figure 3B).
Osteoblast proliferative indices determined ex vivo by
BrdU staining of cultured calvarial osteoblasts were com-
parable to WT values (data not shown). Additionally, theosteoid was markedly reduced in toluidine blue- and
Goldner-stained sections and by quantification of osteoid
thickness, surface, and volume (Figure 3C). Osteoid thick-
ness is determined by the rate of osteoid deposition by
osteoblasts and the rate of osteoid mineralization. Miner-
alization lag time (Mlt) was decreased in mutant mice.
Hence, osteoblasts are producing osteoid at a slower
rate as suggested by low MAR, but the osteoid is also
being mineralized at a faster rate than in WT controls,
suggesting an inherent alteration in both the quantity and
quality of the osteoid matrix.Cell 127, 291–304, October 20, 2006 ª2006 Elsevier Inc. 293
Figure 2. Crtap/Mice Are Smaller and Have Osteo-Chondrodysplasia, Kyphosis, and Severe Osteopenia Compared to WT Lit-
termates
(A and B) Radiographs of 6-month old mice showing pronounced kyphosis (boxed) in Crtap/ versus littermate control.
(C) Weight-curve analysis comparing Crtap/ and WT male mice (mean ± SD, N = 10, p < 0.01) and female mice (N = 10, p < 0.01, data not shown).
(D) Rhizomelia and severe osteopenia are seen in this radiograph of a 6-week-old Crtap/ versus control hind limb.
(E) L3 vertebral bodies from Crtap/ and WT mice were embedded in methyl-methacrylate, sectioned, and stained with Von Kossa. BV/TV values
shown are from 3-month-old male mice (mean ± SD, N = 6, p < 0.01).
(F) Comparison of 4-week-old proximal tibia sections from Crtap/ and WT mice stained with H&E. Note thin trabeculae in the epiphyseal ossifi-
cation center and dysplastic proliferating chondrocytes in Crtap/ mice.Because bone formation and resorption are coupled in
vivo, we looked for an osteoclastic defect. The low bone
mass in Crtap/ mice, however, is likely not due to ac-
celerated bone resorption since osteoclast numbers are
normal in vivo (Figure S1), and ex vivo osteoclast function
assessed by pit resorption and splenocyte differentiation
was also normal (Figure S1). The absence of a hyper-
resorptive phenotype is supported by the finding of
comparable urinary deoxypyridinoline (Dpd) levels in mu-
tant versus WT mice (Figure 3D). Serum and urinary cal-
cium, phosphorus, and magnesium were normal (data
not shown), excluding a defect in mineral homeostasis.
Hence, Crtap null mice exhibit a severe osteoporosis
characterized by low bone mass, normal osteoblast and294 Cell 127, 291–304, October 20, 2006 ª2006 Elsevier Inc.osteoclast numbers, reduced BFR/BS and MAR, and
decreased osteoid synthesis and Mlt.
CRTAP Can Complex with Mammalian P3H1 and
Is Required for Efficient 3-Hyp Modification
of Fibrillar Collagen
Recently, it was shown that CRTAP copurified with Lepre-
can (P3H1) via gelatin sepharose chromatography in
a screen to identify proteins that bound denatured colla-
gens. However, CRTAP does not contain a 2-oxoglutarate
dioxygenase domain and hence showed no collagen hy-
droxylation activity in vitro (Vranka et al., 2004). To deter-
mine if CRTAP can affect collagen prolyl 3-hydroxylation
in vivo we analyzed collagens a1(I) and a1(II) chains for
Figure 3. Crtap/ Mice Have Functional Osteoblastic Defect and Decreased Osteoid
(A) Histomorphometric analyses of 3-month-old femurs show reduction in BV/TV, trabecular thickness, trabecular number, and increased trabecular
separation (mean ± SD, N = 6, age and sex matched; **p < 0.01).
(B) While mineralizing and osteoblast surfaces were similar, the kinetic indices of bone formation, mineral apposition (MAR), and bone formation rates
(BFR/BS) were significantly reduced in Crtap/ versus controls (mean ± SD, N = 6, age and sex matched; **p < 0.01).
(C) Osteoid synthesis defect in Crtap null mice is demonstrated with Goldner staining (osteoid is stained in red). Osteoid measurements revealed de-
creased osteoid thickness (O.Th), osteoid surface (OS/BS), osteoid volume (OV/BV), and mineralization lag time (Mlt) in Crtap/ versus controls
(mean ± SD, N = 9, age matched; **p < 0.01).
(D) DPD analysis demonstrated comparable urine deoxypiridinoline levels in Crtap/ versus control mice (mean ± SD, N = 6, females, 2–3 months
old).3-Hyp content in Crtap/ and WT mice (Figure 4A). This
was accomplished by resolving the cyanogen bromide
(CNBr) peptides by SDS-PAGE followed by tandem
mass spectrometric analyses of the trypsin digested, spe-
cific CNBr-peptide known to contain the 3-Hyp residue
(Figure 4B). We found that a1(I) chains from bone and
skin collagen and a1(II) chains from cartilage of mutant
mice completely lacked the 3-hydroxyl modification at
the single substrate proline residue near their carboxy
terminus (Figure 4C and Figure S2). The SDS-PAGE re-
sults showed slight but significant slowing of the major
cyanogen bromide (CB) peptides from cartilage type II
collagen, suggesting overmodification of lysine residues
(Figure 4B). These data indicate that prolyl 3-hydroxylation
of fibrillar type I and II collagens is absent in Crtap/
mice. To determine if collagen fibrils were altered structur-
ally by loss of the prolyl 3-hydroxylation at this singleresidue in the triple-helical domain, we performed ultra-
structural studies from mutant and WT mice. Collagen
fibrils in mutant dermis and cartilage were thicker than in
WT (skin [mean ± SD]: WT = 85 ± 7 nm versus mutant =
117 ± 9 nm, p < 0.0001; cartilage: WT = 85 ± 10 nm versus
mutant = 117 ± 9 nm, p < 0.0001), suggesting that loss
of this 3-Hyp residue may affect collagen fibril assembly
(Figure 4D). To evaluate collagen intracellular processing,
we performed collagen synthetic studies in mouse osteo-
blasts by steady state and pulse chase assays and
found that type I procollagen chains were overmodified,
based on a slower mobility, and, apparently, secreted
in higher amount by Crtap/ cells (Figures 4E and 4F).
The latter was consistent with our observations on mutant
primary calvarial osteoblasts in vitro, showing increased
collagen staining (Van Gieson). Moreover, the in vivo
observation of decreased mineralization lag time, i.e.,Cell 127, 291–304, October 20, 2006 ª2006 Elsevier Inc. 295
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increased mineralization rate, correlated in vitro with the
increased number of mineralization nodules in mutant
versus control calvarial osteoblasts (Figure 4G). Hence,
failure to 3-hydroxylate a single proline in fibrillar collagens
I and II is associated with posttranslational overmodifica-
tion, apparent altered rate of collagen production and
matrix mineralization in osteoblasts, and increased fibril
diameter.
Because collagen prolyl 3-hydroxylation takes place
in the endoplasmic reticulum (ER), we determined the
CRTAP subcellular localization. Immunofluorescence (IF)
staining of Cos7, chick embryo chondrocytes (CEC), or
MC615 cells transfected with an myc-tagged CRTAP ex-
pression construct showed a widespread and reticular
pattern of distribution in the endoplasmic reticulum, with
no nuclear staining. A partial colocalization with the Golgi
was also observed, depending on the cell type that was
examined; in particular, this was minimal or not detected
in the mouse chondrocyte cell line MC615 (Figures
5A–5C).
Given the data indicating that CRTAP affects P3H1
function in vivo, we tested whether both proteins coex-
isted in a complex by subjecting gelatin binding protein
fractions to velocity sedimentation on a sucrose gradient.
P3H1 sediments to fractions 12/13, which also contain
some CRTAP and Cyclophilin B (Figure S3A). Free CRTAP
and Cyclophilin B sediment to fractions 19 and 23, respec-
tively. The cosedimentation suggests that these proteins
form a complex. This complex was isolated and analyzed
by laser-light scattering. The molecular mass of the com-
plex was 154.6 kDa (Figures 5D and 5E). This corresponds
well to the calculated molecular mass of 155 kDa of a 1:1:1
complex of P3H1, CRTAP, and Cyclophilin B. Further in vi-
tro evidence that P3H1 and CRTAP could directly interact
came from Western analysis on affinity chromatography
eluted proteins after binding to either CRTAP or P3H1 an-
tibody columns. In both cases, using the appropriate anti-
body, we were able to detect the corresponding protein
supporting that CRTAP and P3H1 can form a stable com-
plex (Figures S3B and S3C).Loss of CRTAP Is Associated with Recessive
Osteogenesis Imperfecta
CRTAP maps to human chromosome 3p22.3 (Tonachini
et al., 1999). Ward et.al. (2002) described a large consan-
guineous family in Quebec affected with a distinct ‘‘rhizo-
melic’’ form of osteogenesis imperfecta, termed OI type
VII (Figure 6A) (Ward et al., 2002). This recessive form of
OI was mapped to the short arm of chromosome 3 to
a 5cM minimal interval localized between markers
D3S2423 and D3S1561 (Labuda et al., 2002). This region
contains 18 genes including CRTAP (Figure 6B). Given
the rhizomelic osteochondrodysplastic phenotype of
Crtap null mice, we hypothesized that CRTAP loss of func-
tion could cause OI VII. We found levels of CRTAP mRNA
in cultured skin fibroblasts from two affected family mem-
bers (patients IV-3 and V-7 of the Ward et al., 2002 pedi-
gree) to be 10% those of four unrelated control subject
cells after normalization to a single copy, constitutively ex-
pressed gene (b2-microglobulin) (Figure 6C, Table S1).
Western blot analysis of patient and control fibroblast pro-
tein extracts showed decreased levels of CRTAP protein
paralleling the change in mRNA (Figure 6D). The finding
of residual normal-sized CRTAP suggested the possibility
of a hypomorphic allele in this family. Sequence of the
CRTAP coding and flanking intronic regions failed to iden-
tify a mutation, but all sites known to be polymorphic were
homozygous in accordance with the consanguinity in this
family.
RT-PCR amplification of RNA isolated from OI VII and
control fibroblasts treated with and without cycloheximide
demonstrated an additional longer CRTAP transcript in OI
VII fibroblasts (Figure 6E). Sequence analysis of the longer
transcript indicated the inclusion of 73 bp of intron 1. In
CRTAP genomic DNA from an OI VII patient, we identified
a single nucleotide change (c.472 1021C>G) in intron 1
consistent with activation of a cryptic splice donor site
and the inclusion of a 73 bp cryptic exon (position
1094 to 1021 50 of exon 2) into the CRTAP cDNA
(Figure 6F). This longer transcript contains a frame shift
and is predicted to become degraded by the NMDFigure 4. Crtap/ a1(I) and a1(II) Collagens Lack the Unique 3-Hydroxyproline, Are Overmodified, and Form Fibrils with
Increased Diameter
(A) Schematic diagram of a procollagen showing the 3-Hyp position in a1(I) and a1(II) collagens.
(B) Electrophoretic migration of cyanogen bromide-derived peptides generated from type I and type II collagens. CB peptides CB6 and CB9, seven
containing the unique 3-Hyp residue, were analyzed by MS peptide mapping.
(C) The tryptic digest of a1(I)CB6 peptide was analyzed by tandem mass spectrometry. Top two panels (a, b) show the parent ions in the mass spectra
from WT andCrtap/ bone differing by 16 atomic mass units (1563 versus 1547) consistent with additional oxygen atom in WT peptides. Bottom two
panels (c, d) show the MS/MS fragmentation spectra with daughter ions localizing the 16 mass difference to residues carboxy-terminal to the y6 po-
sition, consistent with absence of oxygen from P# in the Crtap/ peptide.
(D) Transmission electron micrographs show increased diameter in dermal fibroblast collagen fibrils from the Crtap/ mice versus controls (mag-
nification: 372 K).
(E) Steady-state labeling of cultured primary calvarial mouse osteoblasts showing delayed migration of procollagen/collagen chains in Crtap/
samples consistent with overmodification. Procollagen chains were precipitated from culture medium, +/ treatment with pepsin, and run on
a 5% polyacrylamide-urea-SDS gel under reducing or nonreducing conditions, as indicated and repeated in two independent experiments.
(F) Collagen pulse-chase assays suggest increased rate of collagen secretion in mouse mutant osteoblasts versus WT controls. The medium fractions
run on a 5% polyacrylamide-urea-SDS gel under nonreducing conditions are shown (the cell fraction gel is not shown). The experiment was normal-
ized by total number of cells and repeated in three independent experiments.
(G) Crtap/ primary calvarial osteoblasts cultured for 21 days in vitro show qualitative increase of collagen staining (Van Gieson) and number of
mineralization nodules (Von Kossa) compared to WT controls (N = 3).Cell 127, 291–304, October 20, 2006 ª2006 Elsevier Inc. 297
Figure 5. CRTAP Is Widely Localized in the Cell and Interacts with P3H1 in the rER
(A) Confocal microscopic image of Cos7 cells transfected with an myc-CRTAP construct and stained with anti-myc monoclonal antibody (green)
showing a subcellular reticular pattern of expression. Nuclei were stained with propidium iodide (red).
(B) MC615 mouse chondrocyte cells were cotransfected with an myc-CRTAP construct (red) and an ER-targeted GFP (green) with Hoechst stained
nuclei (blue). The merged image shows colocalization of CRTAP with the ER.
(C) MC615 cells were cotransfected with myc-CRTAP (red) and a Golgi-targeted EYFP (green) with Hoechst stained nuclei (blue). The merged image
suggests no overlap between CRTAP and the Golgi.
(D) Fractions from the gelatin Sepharose column were run on a molecular sieve column attached to a laser-light scattering instrument. A peak at 155
kDa was found that contains P3H1. The elution profile of a fraction containing P3H1 on a Superose 12 column is shown. The light-scattering signal
(red), refractive index signal (blue), and absorbance at 220 nm (green) are shown. Using the data of light scattered at multiple angles, one can
determine the absolute mass, independently from the elution position of the column.
(E) The major peak (delineated by the two vertical bars in [D]) was analyzed by this method and the molar mass assessed. A molecular mass of 154.6
kDa was determined (black horizontal line).mechanism. The point mutation in intron 1 was confirmed
in four OI VII patients while the sequencing of eight unaf-
fected members of the family showed that they were
either carrier for the mutation (parents of affected) or WT
(Figure S4).
To confirm that the decrease ofCRTAP expression in OI
VII patients translated to a biochemical alteration in fibrillar
collagen, we performed a tandem mass spectrometry
(MS/MS) analysis of trypsin-digested pepsinized collagen
derived from the two patient versus control fibroblast-
conditioned media. A significant (and variable) proportion
of unhydroxylated Pro was found in patients but not in
control cell medium collagen (Figure 6G). An identical re-
sult was seen in type I collagen extracted from an OI VII
bone sample compared to unrelated controls (data not
shown). Together, these findings strongly indicate that hy-
pomorphic loss of function of CRTAP causes OI type VII.298 Cell 127, 291–304, October 20, 2006 ª2006 Elsevier Inc.This evidence led us to ask if a more severe human OI
phenotype would be caused by complete loss of function
of CRTAP. Such a mechanism would likely be found in
pedigrees with recurrence of severe OI in children born
to unaffected parents and associated with collagen over-
modification. Until now, these cases had been attributed
to either germline mosaicism and/or inheritance of an un-
known recessive mutation. We studied one such consan-
guineous family in which four pregnancies were affected
with short limbs and multiple fractures (Figure 7A). The di-
agnosis of recurrent OI type II was made based on the clin-
ical features and the biochemical finding of type I collagen
overmodification. However, COL1A1 or COL1A2 muta-
tions could not be identified. Sequence analysis ofCRTAP
coding regions from probands VIII-3, VIII-5, and VIII-12
DNAs detected a homozygous single base pair (T) deletion
in exon 4 (c.879delT). This deletion causes a frameshift
Figure 6. A CRTAP Splice Mutation Causes OI Type VII
(A) Left panels show upper extremity radiographs of a 2.5-year-old girl with OI type VII, showing selective shortening of the humeri (rhizomelia) and
bowing deformity. Right panel shows lower extremity radiograph of the same patient, showing bilateral coxa vara and bowing deformity.
(B) Schematic diagram of human chromosome 3 with CRTAP localization within the 5cM OI VII critical region defined by the markers D3S2324 and
D3S1561.
(C) Q-PCR analysis demonstrates levels of CRTAP mRNA in two OI VII patients (5 and 6) to be about 10% those of controls (1–4) (mean ± SD, three
experiments).
(D) Western blot of fibroblast lysates shows decreased levels of CRTAP protein in OI VII samples normalized to g-tubulin. Residual protein is detect-
able in patients when the lysate is overloaded (far right lane).
(E) PCR amplification of the exons 1–4 of CRTAP cDNA from OI VII and control fibroblasts treated with and without cycloheximide. An additional,
longer transcript in the OI VII cells suggests the presence of a splice mutation. Proportion of mutant species is increased relative to WT in OI VII cells
treated with cycloheximide (MW = molecular weight standards).
(F) Diagram showing the single base change (asterisk) in intron 1 (C>G) that generates a novel splice donor site. Utilization of an upstream acceptor
site results in the inclusion of a cryptic 73 bp exon into theCRTAPmRNA. The longer transcript contains a frameshift with a stop codon 12 amino acids
downstream of exon 1.
(G) Mass spectrometric analyses of pepsinized a1(I) collagen extracted from patient and control fibroblast-conditioned media show evidence of un-
der-3-hydroxylation of proline in OI VII a1(I) chains. Residual and variable levels of 3-Hyp in the two patient samples is consistent with the proposed
hypomorphic nature of this mutation.with a premature termination codon 15 amino acids down-
stream and would be expected to cause a null allele due
to nonsense-mediated decay. The parents of VIII-3 and
VIII-5 (VII-1, VII-2) were asymptomatic but were carriers
for the deletion (Figure 7A). Biochemical and MS/MS anal-
ysis of collagen from cultured fibroblasts from the pro-
band confirmed collagen overmodification and showedthat the target proline was underhydroxylated (Figure 7B).
CRTAP protein could not be identified in fibroblasts from
VIII-12 (Figure 7C). Finally, real-time PCR performed on
RNA extracted from cultured fibroblasts showed that
they contained 10% of the amount seen in the OI type
VII cells and about 1% of that seen in control cells
(Figure 7D, Table S1).Cell 127, 291–304, October 20, 2006 ª2006 Elsevier Inc. 299
Figure 7. Loss of Function of CRTAP in Severe OI Type II
(A) Pedigree of an eight generation, consanguineous family (only the last two generations are depicted) showing multiple affected individuals with
short limbs and multiple fractures and diagnosis of severe OI type II. Homozygous single base pair (T) deletion inCRTAP exon 4 was found in affected
patients including VIII-3, VIII-5, and VIII-12. Unaffected parents (VII-1 and VII-2) were carriers for the mutation.
(B) Electrophoretic and MS/MS analyses of pepsinized medium collagen from OI II patient fibroblasts confirmed overmodification (left panel) and
about 40% residual 3-Hyp compared to control.
(C) Western blot analysis revealed complete absence of CRTAP protein in fibroblast lysate from an OI II patient (VIII-12) versus control.
(D) Real time q-PCR demonstrated levels of CRTAP mRNA in OI II (4) that were 1% compared to normal control (3) and 10% of the OI VII (1–2) fibro-
blasts (Mean ± SD, three experiments).Together, these data support that loss of function of
CRTAP in humans is associated with a clinical spectrum
of recessive OI. At the milder end of the spectrum, the clin-
ical picture is one of bone fragility and rhizomelia seen in
OI type VII; at the severe end, the phenotype is similar to
lethal OI type II.
DISCUSSION
Prolyl 3-hydroxylation (Majamaa, 1981; Risteli et al., 1977;
Tryggvason et al., 1979) has been a poorly understood
collagen posttranslational modification. It occurs in fibril-
forming type I and II collagens uniquely, at only one proline
residue in the a1 chains (residue 986 of the triple-helical300 Cell 127, 291–304, October 20, 2006 ª2006 Elsevier Inc.domain) but more frequently in network-forming type IV
collagen. We show that loss of Crtap causes an osteo-
chondrodysplasia characterized by short stature, kypho-
sis, and severe osteoporosis in mice. CRTAP can bind
P3H1, and although the binding is not essential for enzy-
matic activity of P3H1 in vitro, CRTAP appears to be nec-
essary for efficient 3-hydroxylation of fibrillar collagen
prolyl residues in vivo. This could be due to its facilitation
of P3H1 association with nascent procollagen chains. In
humans, 10% residual CRTAP results in a rhizomelic
form of recessive OI, while complete loss of the protein
leads to a more severe form of OI. In both instances, the
loss of protein is associated with marked decrease in
3-hydroxylation of the target prolyl residue in the triple-
helical domain of type I collagen molecules.
CRTAP can form a complex with P3H1 in the rER where
they can bind to pro-a collagen chains to mediate this
post-translational modification. The major effects of
CRTAP loss of function are on collagen modification, intra-
cellular trafficking, and extracellular fibril assembly. The
end result of these abnormalities is a functional defect in
osteoid production and mineralization rate. Collagen over-
modification usually reflects a delay in triple-helix forma-
tion, and this suggests a function for CRTAP and/or
3-Hyp in the regulation of collagen triple-helical assembly
within the cell. The increased collagen fibril diameter out-
side of the cell and decreased osteoid volume and thick-
ness in bone suggest that there is decreased deposition
of osteoid. This may in part be due to inefficient fibril for-
mation in the face of perhaps even increased procollagen
secretion. The low osteoid thickness and MAR in the pres-
ence of normal numbers of osteoblasts support our con-
clusion that the net amount of bone matrix produced by
these cells is abnormally low. The low Mlt suggests that
the osteoid produced is mineralized in an abnormally
fast manner. These effects, together, cause a severe low
bone-mass phenotype that partially mimics observations
made in children with OI (Rauch et al., 2000). Bone resorp-
tive activity, however, was not increased inCrtap deficient
mice. Thus, the findings suggest that the osteoporosis of
these mice is due to deficient bone formation.
In addition to its important structural functions, type I
collagen serves as a critical component in maintaining in-
teractions with cell surfaces, other ECM molecules, and
growth and differentiation factors. Over 50 molecules
interact with type I collagen and many of the over 300 hu-
man mutations that have been reported in type I collagen
genes affect sequences that are in these interaction
domains (Di Lullo et al., 2002). For example, differential
prolyl 4-hydroxylation of the collagen GXPGER sequence
(which may occur in forms of OI with collagen overmodifi-
cation) has been shown to affect collagen binding speci-
ficity to cell surface a1b1 versus a2b1 integrin (White
et al., 2004). In a similar fashion, loss of 3-Hyp and/or
CRTAP may also lead to dysregulation of specific collagen
interactions.
CRTAP is related to theP3H1,P3H2, andP3H3 family of
genes and shares a tetratricopeptide-like domain located
at their amino-terminal portions. P3H1 is localized specif-
ically to tissues that express fibrillar collagen, suggesting
that other P3H family members may be responsible
for modifying basement membrane collagens. Hence,
CRTAP may have diverse functions in multiple tissues re-
lated to prolyl 3-hydroxylation but also perhaps indepen-
dent of this process.
Our data indicate that a quantitative defect in CRTAP
causes OI type VII. In this case, an intronic mutation is as-
sociated with activation of a cryptic splice site, leading to
generation of a longer transcript with a translational frame-
shift. This altered splicing occurs in most transcripts, as
shown by 10% residual normal CRTAPmRNA and protein
in patient fibroblasts. The clinical description of this condi-
tion as a ‘‘rhizomelic’’ form of OI correlates well with a func-tion for CRTAP in cartilage and in bone. Instead, complete
absence of CRTAP as a result of a frameshift that leads to
NMD in all transcripts gives rise to a far more dramatic
phenotype that is similar to a much more severe and po-
tentially lethal form of OI. Thus, variable CRTAP loss of
function is a mechanism for recessive OI and may contrib-
ute to a proportion of apparent de novo cases whose pre-
vious diagnosis was solely based on biochemical alter-
ations in type I collagen. Traditionally, the recurrence
risk assigned to unaffected parents who have a child
with biochemically proven OI is quoted as up to 2% be-
cause of germline mosaicism (Cohn et al., 1990; Pepin
et al., 1997). Our data suggest that in some instances,
the diagnosis of OI secondary to the finding of classical
type I collagen overmodification in cultured fibroblasts is
due to recessive mutations in CRTAP with a recurrence
risk of 25%. Moreover, our data suggest that there may
be as yet undescribed connective tissue disease pheno-
types that are due to dysregulation of prolyl 3-hydroxyl-
ation in other collagens, e.g., types III, IV, and V collagens.
Such conditions might present a clinical spectrum more
related to Ehlers Danlos syndrome (collagen III and/or V)
and Alport syndrome (collagen IV). Finally, loss of the
enzymatic activity of P3H1 might mimic loss of CRTAP,
while the effects of mutations in CYPB remain to be
explored.
EXPERIMENTAL PROCEDURES
ISH, Immunohistochemistry (IHC), IF, and Western Blot
ISH on paraffin-embedded tissues was performed as described previ-
ously (Morello et al., 2001). The Crtap RNA in situ probe contains the
full-length open-reading frame (Morello et al., 1999). IHC analysis
was performed with anti-CRTAP antisera as described elsewhere
(Castagnola et al., 1997). Cell transfection, fixation, permeabilization,
and IF procedures were performed as previously described (Tonachini
et al., 2004). The myc-tagged CRTAP cDNA was inserted into
pcDNA3.1 myc/his (Invitrogen). ER- and Golgi-targeted fluorescent
GFP and EYFP constructs were from BD Clontech. MC615 cells (Mal-
lein-Gerin and Olsen, 1993) were transfected with Fugene6 according
to manufacturer’s instructions (Roche). Alexa594 or Oregon
Green514-conjugated goat anti-mouse antibody (Invitrogen) were
used to detect the anti c-myc 9E10 monoclonal antibody (Evan
et al., 1985) and nuclei were stained with Hoechst 33258 or with propi-
dium iodide. Images were acquired with either a FV500 confocal mi-
croscope (Olympus) or with an Axiovert 200M (Zeiss). Western blots
were performed using an anti-CRTAP polyclonal antibody and normal-
ized with anti- g-tubulin mouse monoclonal antibody (Sigma).
Targeting, Southern Blot, Northern Blot, RT-PCR, and
Quantitative PCR (Q-PCR)
The Crtap targeting vector (shown in Figure 1) was electroporated into
AB2.2 embryonic stem (ES) cells. Homologous recombination was
identified by Southern analysis. Germ-line transmission of the mutant
allele into C57BL6 was obtained. For Northern blot and RT-PCR, total
RNA was extracted from tissues or cells using Trizol reagent (Invitro-
gen). Osteoclast RNA was a gift of Florent Elefteriou (UTHSC, San An-
tonio, TX). The Northern was probed with the same Crtap probe used
for ISH. cDNA synthesis was performed using the SuperScript III First
Strand RT-PCR kit (Invitrogen). Q-PCR was performed as described in
the Supplemental Data.Cell 127, 291–304, October 20, 2006 ª2006 Elsevier Inc. 301
Fibroblast Cultures and DNA Sequencing
Unrelated control fibroblasts used for Western, real-time, and RT-PCR
experiments were primary human skin fibroblasts that matched the OI
VII/II skin fibroblasts passage number and were fully comparable. They
were grown in DMEM, 10% FBS. When indicated, cycloheximide
(100 mg/ml) was added for 5 hr and then RNA and cDNA were prepared
as described above. Patient samples were PCR amplified using
intron-specific primers and directly sequenced with dye terminator
chemistry. Single nucleotide polymorphisms were compared with
the Weizmann Institute of Science database (www.genecards.org).
CRTAP mutations are described with the Ensembl gene ID
ENSG00000170275 as the reference sequence.
Clinical Data
The OI type II family (Figure 7A) is of Indian descent, and the parents of
the proband (VIII-3) are second cousins but also related by a more
complex consanguinity loop with common ancestors seven genera-
tions back. The first pregnancy was a spontaneous loss and the sec-
ond (VIII-2) was found to have very short limbs with multiple fractures
at 16 weeks gestation, consistent with OI type II. The third pregnancy
was terminated at 16 weeks for the same findings, and cells grown
from skin of that fetus synthesized abnormal type I procollagen, in
which all chains were overmodified. Sequence of the cDNAs from
COL1A1 and COL1A2 were normal. Cells from VIII-5 and VIII-6 all
made overmodified type I procollagen molecules. The family had two
unaffected children. Four years after the birth of VIII-6, the mother’s
brother (VII-3) and his wife (VII-4) had an affected pregnancy (ultra-
sound examination) that was terminated.
Radiographs, Bone Histology/Histomorphometry, and Tissue
Staining
Radiographs were obtained by Faxitron (Faxitron X-ray Corp., Wheel-
ing, IL). Routine histologic analysis of paraffin-embedded long bone
and growth plates was done as per standard protocols. Histomorpho-
metric analysis of static and dynamic parameters (using 20 mg/kg cal-
cein injection) of bone resorption, formation, and volume was carried
out according to standard procedures (Parfitt et al., 1987) in 12
week-oldCrtap/ and WT mice (N = 6 each sex and genotype) prox-
imal tibial secondary spongiosa using the Osteomeasure image anal-
ysis system (OsteoMetrics, Inc., Decatur, GA). Goldner and Von Kossa
staining were performed using standard protocols.
Collagen Studies and Mass Spectrometry
Collagen steady-state and pulse-chase assays were performed as de-
scribed (Bonadio et al., 1985; Kuznetsova et al., 2004). Primary calva-
rial osteoblasts were labeled with 70 mCi of L-[2,3,4,5-3H] proline. For
pulse-chase assays, cells were labeled for 4 hours and then chased
with fresh medium containing cold proline at time 0. Both medium
and cell layer were harvested at 300 intervals and analyzed separately.
Collagens were obtained by overnight pepsin digestion (55 mg/ml) of
procollagen samples.
For quantification of 3-Hyp in collagen preparations obtained from
tissues or skin fibroblast cultures, CNBR-derived peptides (CB pep-
tides) or pepsinized collagens were isolated and tryptic digests pre-
pared for MS/MS. See Supplemental Data for mass spectrometry con-
ditions. Transmission electron microscopy was performed on skin and
sternal cartilage biopsies from WT and mutant mice (N = 3). The fibril
diameter of ten fibrils in each of five different areas per mouse was
measured (N = 150 total measurements each genotype).
Affinity Column Purification, Velocity Sedimentation,
Laser-Light Scattering
For affinity column purification and velocity sedimentation, see Sup-
plemental Data.
P3H1 associations, based on the measured molar masses, were ob-
served using a multi-angle light scattering (MALS) instrument (DAWN302 Cell 127, 291–304, October 20, 2006 ª2006 Elsevier Inc.Eos, Wyatt Technology). The instrument was placed in line with a UV
detector, refractive index detector (RI, Wyatt), and a quasi-elastic light
scattering detector (QELS, Wyatt) during size-exclusion chromatogra-
phy (SEC). SEC was performed with a Superose 12 10/300 GL column
(Amersham Biosciences) equilibrated in phosphate-buffered saline
with a flow rate of 0.2 ml/min. Signals from the UV, RI, and MALS de-
tectors were normalized using bovine serum albumin. Monodisperse
regions under the peak were analyzed. The weight-averaged molar
masses (Mw) were reported based on the average protein concentra-
tion for the peak area analyzed. The peak area analyzed was approx-
imately 75%.
DPD Assay, Osteoblasts, and Osteoclasts In Vitro Studies
The deoxypyridinoline crosslinks (DPD) assay for free DPD was per-
formed using a Metra DPD EIA kit (Quidel) according to manufacturer’s
instructions, and results were normalized to creatinine levels (Creati-
nine Assay kit, Quidel). In vitro cultures of primary osteoblasts (N = 3)
from P4 mice were established as previously described (Kuznetsova
et al., 2004). Van Gieson and Von Kossa staining were performed ac-
cording to standard protocols. Osteoclasts were generated from sple-
nocytes with M-CSF and RANKL (10 ng/ml), stained for TRAP activity,
and counted, as described previously (Xing et al., 2002).
Statistical Analyses
Data are expressed as mean values ± standard deviation (SD). Statis-
tical significance was computed using the Student’s t test. A P value <
0.05 was considered statistically significant.
Supplemental Data
Supplemental Data include four figures, one table, and experimental
procedures and can be found with this article online at http://www.
cell.com/cgi/content/full/127/2/291/DC1/.
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